Walt Ling

Mr. Walt Ling is the Chief Executive Officer of ACT Genomics Co., Ltd. He has over 25 years of experience in the medical device industry with a broad base of management and operational experience covering strategy, sales, marketing, finance, clinical applications, technical service and human resources.

‍

Prior to joining ACT Genomics, Mr. Ling was the Vice President and Managing Director APAC for Oxford Immunotec, a company focused on infectious disease solutions. During his tenure at Oxford Immunotec, he was responsible for executing regional commercial operations and business expansion strategies. Mr. Ling was also responsible for the regional integration efforts in the recent acquisition of the company by PerkinElmer. Prior to Oxford Immunotec, Mr. Ling was the Vice President and Managing Director APAC for Leica Biosystems, a medical device company that develops and supplies clinical diagnostics to the pathology market.

‍

Mr. Ling received a Masters of Business Administration degree from the J.L. Kellogg School of Management at Northwestern University and a Bachelors of Business Administration degree from the University of Texas at Austin. Mr. Ling is a member of the Singapore Chapter of the Young Presidents Organization.